Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridIssever, Kubilay/0000-0002-1376-1488
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authoridDemircan, Nazim/0000-0001-6630-5278
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidIssever, Kubilay/ABP-1093-2022
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.authorwosidDemircan, Nazim/HHY-8715-2022
dc.contributor.authorGokyer, A.
dc.contributor.authorKucukarda, A.
dc.contributor.authorKostek, O.
dc.contributor.authorHacioglu, M. B.
dc.contributor.authorSunal, B. S.
dc.contributor.authorDemircan, N. C.
dc.contributor.authorUzunoglu, S.
dc.date.accessioned2024-06-12T11:14:10Z
dc.date.available2024-06-12T11:14:10Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackgroundSarcopenia is related to poor prognosis and drug toxicities in solid tumors. The aim of our study is to investigate the predisposition of patients with metastatic colorectal carcinoma who started regorafenib treatment to sarcopenia and prolonged survival.MethodsPatients with metastatic colorectal carcinoma who receives regorafenib were search retrospectively. Dose-limiting toxicity was defined as dose reduction or toxicity requiring drug withdrawal. Sarcopenia evaluation was made with computed tomography performed within a month before treatment. Progression-free survival and overall survival were estimated.ResultsThirty-six patients were found as suitable for the study. 63.9% of patients were found as basally sarcopenic. Dose-limiting toxicity occured 13 of 23 patients (56.5%) with basal sarcopenia, whereas only 1 of 13 patients (7.6%) with no sarcopenia exhibited dose-limiting toxicity (p=0.005). Three patients suffered from grade 3-4 toxicity. Hand-foot syndrome, hypertension, and mucosal rash were the most seen side effects. Mean regorafenib treatment duration was 3.36 months. There was no significant difference in the progression-free survival (PFS) and the overall survival (OS) between sarcopenic patients and patients with no sarcopenia. Durations were as OS 24.2 weeks in patients with sarcopenia (95% CI 16.7-31.7), 28.1 weeks in patients with no sarcopenia (95% CI 20.5-35.7) (p=0.36), and as PFS 14.2 weeks in patients with sarcopenia (95% CI 12.1-16.4), 14.8 weeks in patients with no sarcopenia (95% CI 9.7-20.1) (p=0.65).ConclusionDose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.en_US
dc.identifier.doi10.1007/s12094-019-02080-4
dc.identifier.endpage1523en_US
dc.identifier.issn1699-048X
dc.identifier.issn1699-3055
dc.identifier.issue11en_US
dc.identifier.pmid30868388en_US
dc.identifier.scopus2-s2.0-85062950833en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1518en_US
dc.identifier.urihttps://doi.org/10.1007/s12094-019-02080-4
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23832
dc.identifier.volume21en_US
dc.identifier.wosWOS:000493999400009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Int Publ Agen_US
dc.relation.ispartofClinical & Translational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSkeletal Muscle Areaen_US
dc.subjectRegorafeniben_US
dc.subjectDose-Limiting Toxicityen_US
dc.subjectColorectal Canceren_US
dc.subjectBody-Mass Indexen_US
dc.subjectAssociationen_US
dc.titleRelation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafeniben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu